publication date: Jan. 25, 2017

Prostate Cancer Study Shows Only Nuclear-Localized AR-V7 Predictive of Benefit for Patients with Metastatic Disease

Investigators from Memorial Sloan Kettering Cancer Center and Epic Sciences published findings in European Urology that only nuclear localization of AR-V7 protein in circulating tumor cells from metastatic castration-resistant prostate cancer patient blood samples is predictive of therapeutic benefit.

Previous work by the same team, reported in JAMA Oncology, demonstrated that nuclear localized AR-V7 protein in CTCs was predictive of a 76 percent reduction of risk of death for mCRPC patients who received taxane chemotherapy versus Androgen Receptor Signaling inhibitors, Zytiga and Xtandi.

The publication describes the comparison of clinical utility of detecting any AR-V7 protein in CTCs versus the previously described nuclear AR-V7 scoring criteria.

The study analyzed 191 mCRPC patient samples and found that patients with a less restrictive scoring criteria utilizing any AR-V7 expression detected in CTCs exhibited generally poor outcomes on ARSi, Zytiga and Xtandi.

However, approximately 13 percent of the positive patients still responded to ARSi. In contrast, none of the patients with nuclear localized AR-V7 protein expression in CTCs exhibited a response to ARSi, demonstrating superior performance of the nuclear localized approach.

The difference between the scoring criteria also made significant differences in the prediction of therapeutic benefit of switching from commonly utilized ARSi to taxane chemotherapy, with only the … Continue reading CCL Jan 2017 – Study Shows Only Nuclear-Localized AR-V7 Predictive of Benefit for Patients with Metastatic Disease

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.